advertisement
Kiuchi Y 23
Showing records 1 to 23 | Display all abstracts from Kiuchi Y60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Shimizu Y
Clinical Ophthalmology 2015; 9: 475-482
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Nakakura S
Clinical Ophthalmology 2015; 9: 51-56
60685 Morphological features and important parameters of large optic discs for diagnosing glaucoma
Okimoto S
PLoS ONE 2015; 10: e0118920
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Kanamoto T
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60685 Morphological features and important parameters of large optic discs for diagnosing glaucoma
Yamashita K
PLoS ONE 2015; 10: e0118920
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Kiuchi Y
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Nakakura S
Clinical Ophthalmology 2015; 9: 475-482
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Yamamoto M
Clinical Ophthalmology 2015; 9: 51-56
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Tanito M
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60685 Morphological features and important parameters of large optic discs for diagnosing glaucoma
Shibata T
PLoS ONE 2015; 10: e0118920
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Terao E
Clinical Ophthalmology 2015; 9: 51-56
60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Nishiyama M
Clinical Ophthalmology 2015; 9: 475-482
60685 Morphological features and important parameters of large optic discs for diagnosing glaucoma
Kiuchi Y
PLoS ONE 2015; 10: e0118920
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Nagatomi N
Clinical Ophthalmology 2015; 9: 51-56
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Mizoue S
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Tabuchi H
Clinical Ophthalmology 2015; 9: 475-482
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Naito T
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60669 Efficiency, safety, and patient preference of switching from dorzolamide 1%/timolol 0.5% to brinzolamide 1%/timolol 0.5% while maintaining the prostaglandin F2α analog
Kiuchi Y
Clinical Ophthalmology 2015; 9: 475-482
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Matsuo N; Fujisawa Y
Clinical Ophthalmology 2015; 9: 51-56
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Teranishi S
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Fujio Y
Clinical Ophthalmology 2015; 9: 51-56
60524 Comparison of the Toxicity Profile of Benzalkonium Chloride-Preserved Tafluprost and SofZia-Preserved Travoprost Applied to the Ocular Surface
Hirooka K; Rimayanti U
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 156-164
60232 Prostaglandin-associated periorbitopathy in latanoprost users
Tabuchi H; Kiuchi Y
Clinical Ophthalmology 2015; 9: 51-56
